You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天津發展(00882.HK)附屬向金陽利康提反訴 索償逾5,400萬人幣
天津發展(00882.HK)旗下力生製藥(002393.SZ)公佈,關於全資子公司中央藥業涉及重大訴訟的進展。基於金陽利康的違約及提起訴訟的行爲,中央藥業近日向天津市第二中級人民法院提起反訴,要求請求解除《十年協議》。 中央藥業並要求基於《十年協議》收取的金陽利康50萬元人民幣市場保證金不予退還;金陽利康向中央藥業支付未提貨部分損失310萬元人民幣;金陽利康賠償計劃任務考覈量中未完成部分中央藥業對應的利潤4,900萬元人民幣;金陽利康配合中央藥業完成市場交接工作;金陽利康賠償中央藥業重新招商已支出的成本及預估成本;金陽利康承擔本案的訴訟費、保全費、保全保險費等費用。上述訴訟請求合計金額爲5,409萬元人民幣。 案件已經受理,但由於尚未開庭審理,訴訟結果存在不確定性,目前尚不能確定對公司損益的影響,實際影響以法院最終判決爲準。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account